Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Executive Summary
Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics